In this study, we present robust data documenting that the Hsp90 inhibitor 17AAG enhances the anti-neoplastic effect of the commonly used chemotherapeutic drug cisplatin in DLBCL cell lines. Here, HSP90AA1 is linked to diffuse large B-cell lymphoma.